Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
MARCH 24, 2023
The selections feature topics ranging from an analysis of the approval and marketing of biosimilars with a skinny label and their associated Medicare savings, to a discussion of the Philips Respironics recall and the need for reforms to U.S. Characteristics of Prior Authorization Policies for New Drugs in Medicare Part D. N Engl J Med.
Let's personalize your content